Search results
Results From The WOW.Com Content Network
Cholescintigraphy or hepatobiliary scintigraphy is scintigraphy of the hepatobiliary tract, including the gallbladder and bile ducts.The image produced by this type of medical imaging, called a cholescintigram, is also known by other names depending on which radiotracer is used, such as HIDA scan, PIPIDA scan, DISIDA scan, or BrIDA scan.
Gallbladder diseases are diseases involving the gallbladder and is closely linked to biliary disease, with the most common cause being gallstones (cholelithiasis). [1] [2]The gallbladder is designed to aid in the digestion of fats by concentrating and storing the bile made in the liver and transferring it through the biliary tract to the digestive system through bile ducts that connect the ...
Mebrofenin is a chelate composed of two molecules of a lidocaine analogue, attached to a technetium-99m ion. All of the hepatobiliary visualization agents previous to mebrofenin have the same structural composition with changes only of the substituants on the phenyl ring of the lidocaine analogue molecules.
The image produced by this type of medical imaging, called a cholescintigram, is also known by other names depending on which radiotracer is used, such as HIDA scan, PIPIDA scan, DISIDA scan, or BrIDA scan. Cholescintigraphic scanning is a nuclear medicine procedure to evaluate the health and function of the gallbladder and biliary system.
The CCK test may be administered in conjunction with an ultrasound test to visually monitor gall bladder contraction. While the test is usually administered in a supine position Dr. William Smedley of Wilkes Barre, Pennsylvania has detected previously missed gallbladder abnormalities by administering the test in an erect position.
Sincalide is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas.It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.
Non-peptide CCK B receptor antagonists such as L-365,260, L-369,293, YF-476, RP-69758, LY-288,513, PD-145,942 and the CCK B receptor inverse agonist L-740,093 have since been developed, [3] and while all of the drugs developed so far have suffered from limited bioavailability or other issues which have hindered their clinical development ...
We’re living in an era of “tweakments,” where minimally invasive cosmetic procedures like Botox and filler have been reduced to nothing more than an ordinary step in one’s skincare regimen ...